TheraRadar
← Back
Data updated: Jul 17, 2026

UT SW MEDCTR

Pharma
Pharmaceuticals

UT SW MEDCTR is a pharmaceutical company with 1 FDA-approved products.

1988
Since
1
Drugs
-
Trials
0
New Drugs (2yr)

Upcoming FDA Decisions

Full Calendar →
Jul 23, 2026 — Rivoceranib + camrelizumab
5d
Jul 23, 2026 — Rivoceranib + camrelizumab
Aug 10, 2026 — Oveporexton (TAK-861)
+2 more dates (Pro)

UT SW MEDCTR's Key Drugs

UT SW MEDCTR's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

UT SW MEDCTR's Recent FDA Approvals

New NDA/BLA approvals for UT SW MEDCTR over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

UT SW MEDCTR's Therapeutic Areas

Disease areas where UT SW MEDCTR has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.

No indication data

UT SW MEDCTR Pipeline Snapshot

Active clinical trials for UT SW MEDCTR across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • Top drug revenue breakdown
  • • Drug-level revenue analysis

Trial Catalysts

  • • Active trial monitoring
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling